To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gain insights into the U.S. market, valued at $5.9 Billion in 2024, and China, forecasted to grow at an impressive 14.4% CAGR to reach $7.8 Billion by 2030. Discover growth trends in other key regions ...

Karthik and her team aimed to use CRISPR as a way to identify and isolate a protein generated by the bacteria that cause Lyme ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

Chicago-based CRISPR technology company Syntax Bio says it has developed tech which automates the slow, manual process of ...

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

Gene therapy could be a permanent cure for many life-threatening hereditary diseases, and this will only help in the treatment of genetic diseases and cancer ...

Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 195 % for ...